ArashA.HorizonMD

PubMed

• 20 citations
  The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy.
  Dalin Li, Alexander Xu, Emebet Mengesha, Rebecca Elyanow, Rachel M Gittelman, Heidi Chapman, John C Prostko, Edwin C Frias, James L Stewart, Valeriya Pozdnyakova, Phil...> ;Inflammatory Bowel Diseases. 2022 Jul 1
• 7 citations
  Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease.
  Alexander M Xu, Dalin Li, Joseph E Ebinger, Emebet Mengesha, Rebecca Elyanow, Rachel M Gittelman, Heidi Chapman, Sandy Joung, Gregory J Botwin, Valeriya Pozdnyakova, P...> ;Frontiers in Immunology. 2022 Jan 1
• 12 citations
  The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders.
  Dalin Li, Alexander Xu, Emebet Mengesha, Rebecca Elyanow, Rachel M Gittelman, Heidi Chapman, John C Prostko, Edwin C Frias, James L Stewart, Valeriya Pozdnyakova, Phil...> ;Medrxiv. 2021 Dec 8
• 10 citations
  Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.
  Arash A Horizon, Robert J Joseph, Qiming Liao, Steven T Ross, Gary E Pakes> ;HIV/AIDS. 2011 Jun 28
• 36 citations
  Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.
  Cai-Sheng Lu, Arash A. Horizon, Kwan-Ki Hwang, John FitzGerald, Wei-Shiang Lin, Bevra H. Hahn, Daniel J. Wallace, Allan L. Metzger, Michael H. Weisman, Pojen P. Chen> ;Arthritis and Rheumatism. 2005 Dec 1
• 21 citations
  Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus.
  Arash A Horizon, Daniel J. Wallace> ;Expert Opinion on Drug Safety. 2004 Jul 1
• Join now to see all